CGRP: The Peptide Behind Menstrual Migraine and Why Perimenopause Makes It Worse
Some of the best-evidenced "peptide" medicine for women isn't a peptide you take. It's a group of approved drugs that block one: CGRP. Here is how it connects to the menstrual cycle and the menopause transition.
CGRP (calcitonin gene-related peptide) is a signaling peptide released by nerves around the brain's blood vessels and coverings during a migraine attack. It widens blood vessels and amplifies pain signaling, and blocking it can prevent or stop attacks. That's the basis of an entire class of FDA-approved migraine medicines. Its connection to women's health comes through estrogen: attacks often cluster around the drop in estrogen just before and during a period, and the erratic hormone swings of perimenopause can make migraine more frequent for many women. Researchers think estrogen influences how the pain system releases and responds to CGRP, though the details are still being worked out.
Migraine is a women's health condition
A Vanderbilt neurology presentation on migraine in perimenopause and menopause (Brandes, CME slides) summarizes the core numbers from the research literature:
- Migraine is 3 times more common in women than men during the reproductive years (citing Lipton, Headache, 2001).
- 51% to 55% of women with migraine report menstruation as a trigger (citing MacGregor, Neurology, 2004; Couturier, Cephalalgia, 2003).
- In one study, high-frequency headache was reported by 12.2% of perimenopausal women versus 8% of premenopausal women (citing Martin et al., Headache, 2016).
The sex difference is small before puberty and widens after it, which is one of the strongest hints that sex hormones are involved. Our hormonal balance hub collects the site's guides on the cycle and the menopause transition.
What CGRP does in a migraine
During an attack, the trigeminal nerve, which supplies sensation to the face and the coverings of the brain, releases CGRP. CGRP then:
- Dilates blood vessels in the brain's coverings.
- Promotes a kind of nerve-driven inflammation around them.
- Sensitizes pain pathways, so normal sensations (light, sound, movement) feel painful.
Levels of CGRP have been found to rise during migraine attacks in research settings, and infusing CGRP can trigger migraine-like attacks in people prone to migraine. Those findings led to drugs designed to block it.
The estrogen connection
Menstrual migraine: the estrogen drop
The research the Brandes slides summarize links two patterns to estrogen (citing MacGregor, Neurology, 2004): estrogen withdrawal with migraine without aura, and high estrogen with migraine with aura. The classic menstrual migraine is the first type: attacks in the window from a couple of days before bleeding starts into the first days of the period, when estrogen falls sharply.
How estrogen and CGRP interact is an active research question. The leading idea is that estrogen affects how much CGRP trigeminal nerves produce and how sensitive the pain system is to it, so a sudden fall in estrogen leaves the system primed. That's a hypothesis supported by animal and laboratory work, not a settled explanation. Menstrual attacks are often described as longer and harder to treat, which is one reason they get special attention. Our cycle-phase guide explains where the late luteal drop falls in a typical cycle.
Perimenopause: the roller coaster
In perimenopause, estrogen doesn't decline smoothly. It swings, sometimes higher than before, then drops abruptly, and cycles become irregular. If falling estrogen triggers attacks, more frequent and less predictable drops mean more chances for attacks. That fits the Martin study's finding of more high-frequency headache in perimenopausal women. For many women, migraine improves after menopause once hormone levels settle, though that isn't guaranteed, especially for women who start hormone therapy. Our perimenopause guide covers the broader transition.
Hormone therapy and contraception
Estrogen-containing treatments interact with migraine in two ways. Steadier estrogen levels can help some women whose attacks are driven by estrogen drops. But for women who have migraine with aura, contraceptive guidelines advise against estrogen-containing (combined) contraception because of stroke risk; the Brandes slides cite evidence that stroke risk rises with aura frequency. Menopausal hormone therapy uses lower doses and is assessed differently, but aura still needs to be part of the conversation. See our guide to HRT and peptides for how hormone therapy fits with other treatments.
The CGRP-targeted medicines
These are the CGRP-targeting migraine drugs listed by GoodRx's drug-class overview:
| Medicine | Type | Form | Main use |
|---|---|---|---|
| Aimovig (erenumab) | Monoclonal antibody | Monthly injection | Prevention |
| Ajovy (fremanezumab) | Monoclonal antibody | Injection, monthly or quarterly | Prevention |
| Emgality (galcanezumab) | Monoclonal antibody | Monthly injection | Prevention (also cluster headache) |
| Vyepti (eptinezumab) | Monoclonal antibody | IV infusion every 3 months | Prevention |
| Ubrelvy (ubrogepant) | Gepant | Tablet | Acute treatment |
| Nurtec ODT (rimegepant) | Gepant | Dissolving tablet | Acute treatment and prevention |
| Qulipta (atogepant) | Gepant | Tablet | Prevention |
| Zavzpret (zavegepant) | Gepant | Nasal spray | Acute treatment |
Monoclonal antibodies bind CGRP or its receptor for weeks at a time; gepants are small molecules that block the receptor for hours to days. Which one fits depends on how often you get attacks, how predictable they are, your other conditions and your coverage. Dosing for any of these is set by your prescriber and the FDA label.
Women-specific analyses exist for some of these drugs; the Brandes slides reference a women-focused subgroup analysis of an erenumab trial (Pavlovic et al., J Headache Pain, 2020). Whether CGRP drugs work differently for menstrual attacks specifically is still being studied, so treat any claim of a "menstrual migraine drug" with care.
CGRP drugs aren't the only option
CGRP-targeted medicines are often not the first thing tried. Many women do well with established acute treatments such as anti-inflammatory painkillers or triptans, taken early in an attack, and some benefit from short-term prevention timed around a predictable period. Regular sleep, meals and hydration, and identifying non-hormonal triggers also matter. Hormonal approaches, such as smoothing out estrogen drops, can help in carefully selected women without aura. A headache specialist will usually weigh all of these, along with your attack frequency and other health conditions, before reaching for a newer drug. That sequence is often driven by insurance rules as well as medicine, so ask what your plan requires.
Why this belongs on a peptide site
Most of what gets marketed to women as "peptide therapy" is research-grade compounds with little human evidence. CGRP is the opposite case: a peptide whose role in a common women's condition was established through human research, leading to multiple approved, trial-tested medicines. It's a useful benchmark when you're judging other peptide claims. Our mood, stress and sleep hub collects the site's neurology-adjacent guides.
Questions to ask a neurologist or headache specialist
- Do my attacks fit a menstrual migraine pattern? What would help confirm it (a headache diary across three cycles)?
- Do I have migraine with aura, and how does that affect my contraception or hormone therapy options?
- Should I be on a preventive, or is short-term prevention around my period an option?
- Would a CGRP-targeted medicine suit my attack pattern, and is it covered by my plan?
- How should I manage migraine treatment if I'm trying to conceive, pregnant or breastfeeding?
- Could perimenopause explain why my migraines changed, and what changes when periods stop?
Tracking that helps your appointment
A headache diary is one of the most useful tools you can bring. Note the date and time of each attack, its severity, whether you had aura, what you took and whether it worked, and your cycle day. After two or three cycles, a menstrual pattern either shows up or doesn't. If your cycles are irregular in perimenopause, note bleeding days and symptoms like hot flashes and night sweats instead.
When to get urgent care
Seek emergency care for a sudden, severe "worst ever" headache, headache with weakness, numbness, confusion, trouble speaking, vision loss, a stiff neck with fever, or a headache after a head injury. Also see a clinician promptly if your headache pattern changes significantly, if a new headache starts after age 50, or if aura is new or different.
Sources
- Brandes JL. Update in Migraine: Perimenopause, Menopause and Migraine Treatment Implications. CME presentation slides (citing Lipton 2001; MacGregor 2004; Couturier 2003; Martin 2016; Kurth 2005; Pavlovic 2020).
- GoodRx. CGRP inhibitors for migraines.